3,881
edits
Changes
Gene-Specific Template (Updated 9-28-21) (view source)
Revision as of 14:22, 28 September 2021
, 14:22, 28 September 2021no edit summary
{{Under Construction}}
{{Under Construction}}
(''General Instructions –The main focus of these pages is providing a quick reference for cancer associations and linking to internal and external resources providing genetics-related information for the gene of interest. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/recommendations/DNA/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them. The use of bullet points rather than large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author Instructions|<u>Author Instructions</u>]] , [[How to Curate a Gene Page|<u>How to Curate a Gene Page</u>]], and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [Mailto:CCGA@cancergenomics.org <u>Technical Support</u>].'')
==Primary Author(s)*==
==Primary Author(s)*==
Put your text here
Put your text here (''Name and affiliation; EXAMPLE: Jane Smith, PhD, Institute of Genomics'')
EXAMPLE: Jane Smith, PhD, Institute of Genomics
__TOC__
__TOC__
==Gene in Cancer Overview==
==Gene in Cancer Overview==
Put your text here
*Put your text here
*Put your text here
*Put your text here
(''Instruction: Use a list of three bullets, targeting one to three sentences each for gene function, germline associations, and somatic associations. Include gene/protein function in cancer such as tumor suppressor, oncogene or other. The information provided can include high level clinically significant details such as if mutations in this gene confirm or exclude certain diseases. Of note, this gene page is not meant to recapitulate the very detailed content on related linked disease entity pages.'')
EXAMPLE:
*''TP53'' is a well-described tumor suppressor gene that functions in apoptosis, genomic stability and inhibition of angiogenesis (RefSeq, Dec 2016).
*Germline loss-of-function alterations, including deletions, are associated with Li-Fraumeni cancer predisposition syndrome (LFS). Individuals with LFS are at an increased risk of developing cancer, particularly sarcomas (PMID: 20586629, 27621308, 25896519).
*Somatic ''TP53'' alterations are reported at a high frequency across a wide range of tumors, arising in ~30% of all cancer patients (PMID: 25400752, 27239089, cbioportal.org accessed 6/2/21).
==Clinical Cancer Associations (Somatic)==
==Clinical Cancer Associations (Somatic)==
(''Instruction: include references and links to related internal CCGA pages'')
{| class="wikitable"
{| class="wikitable"
|'''Tumor Type'''
|'''Tumor Type'''
|'''Therapeutic Significance (Yes, No or Unknown)'''
|'''Therapeutic Significance (Yes, No or Unknown)'''
|-
|-
|EXAMPLE: Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive (link to internal page through this name)
|EXAMPLE: Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive (link this name to internal page using link icon above)
|EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion, Expression Changes (Biomarker), Somatic Hypermutation
|EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion, Expression Changes (Biomarker), Somatic Hypermutation
|
|
|
|
==Clinical Cancer Associations (Germline)==
==Clinical Cancer Associations (Germline)==
(''Instruction: include references and links to related internal CCGA pages'')
{| class="wikitable"
{| class="wikitable"
|'''Tumor Type'''
|'''Tumor Type'''
|'''Therapeutic Significance (Yes, No or Unknown)'''
|'''Therapeutic Significance (Yes, No or Unknown)'''
|-
|-
|EXAMPLE: Myeloid Neoplasms with Germline ANKRD26 Mutation (link to internal page through this name)
|EXAMPLE: Myeloid Neoplasms with Germline ANKRD26 Mutation (link this name to internal page using link icon above)
|EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion,
|EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion,
|
|
|
|
|
|
|-
|-
|}
|}
==External Links==
==External Links==
Put your text here - Include as applicable links to:
Put your text here (''Instruction: Include as applicable links to: ''
1) Atlas of Genetics and Cytogenetics in Oncology and Haematology,
1) Atlas of Genetics and Cytogenetics in Oncology and Haematology,
2) COSMIC,
2) COSMIC,
15) TICdb - database of Translocation breakpoints In Cancer
15) TICdb - database of Translocation breakpoints In Cancer
16) GeneReviews,
16) GeneReviews,
17) ClinGen, and 18) Any gene-specific databases.
17) ClinGen, and 18) Any gene-specific databases''.)''
EXAMPLES (these may be filled in already)
EXAMPLES (these may be filled in already and if not, click on the link and select edit to change)
'''[http://atlasgeneticsoncology.org/Genes/P53ID88.html ''TP53'' by Atlas of Genetics and Cytogenetics in Oncology and Haematology]''' - detailed gene information
'''[http://atlasgeneticsoncology.org/Genes/P53ID88.html ''TP53'' by Atlas of Genetics and Cytogenetics in Oncology and Haematology]''' - detailed gene information
==References==
==References==
(use "Cite" icon at top of page)
(''Instruction: Use "Cite" icon at top of page for automatic insertion using PMID;'' ''If a PMID is not available, manually add the reference information such as for the example book or internet resource below'')<references />
<references />
===EXAMPLE Book===
===EXAMPLE Book===
===EXAMPLE Internet Resource===
===EXAMPLE Internet Resource===
Author name(s). Date (if possible). page title, website title, web address, and date accessed.
#Cingam, S. R. and Koshy, N.V. (2017). Cancer, Leukemia, Promyelocytic, Acute (APL, APML). https://www.ncbi.nlm.nih.gov/books/NBK459352/ Accessed August 3, 2018.
#Cingam, S. R. and Koshy, N.V. (2017). Cancer, Leukemia, Promyelocytic, Acute (APL, APML). https://www.ncbi.nlm.nih.gov/books/NBK459352/ Accessed August 3, 2018.
==Notes==
==Notes==
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.